M&A Deal Summary |
|
|---|---|
| Date | 2022-03-01 |
| Target | Aspen Pharmacare Holdings - Prescription Medicines |
| Sector | Medical Products |
| Buyer(s) | Acino |
| Sellers(s) | Aspen Pharmacare |
| Deal Type | Divestiture |
| Deal Value | 105M EUR |
SEARCH BY
Try For Free 7-Day Free Trial
Acino is a pharmaceutical company focused on developing, manufacturing and marketing well-proven and innovative pharmaceuticals in novel drug delivery forms. Acino was founded in 1836 and is based in Zurich, Czech Republic.
| DEAL STATS | # |
|---|---|
| Overall | 6 of 7 |
| Sector (Medical Products) | 2 of 2 |
| Type (Divestiture) | 5 of 5 |
| Country (South Africa) | 2 of 2 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2021-04-01 |
IlmixGroup - Select Portfolio of Prescription Pharmaceutical Products and Food Supplements
Saint Petersburg, Russia IlmixGroup's Select Portfolio of Prescription Pharmaceutical Products and Food Supplements includes eight prescription pharmaceutical assets and food supplements in the areas of gynecology, gynecologic oncology, urology, and dermatology. The portfolio includes Indinol Forto, Cervicon-DIM, Indinol, Epigallate, Promisan, Indigal, and other clinical assets that are currently under development. These products are mainly used for the prevention and treatment of endometriosis, myoma, cervical dysplasia and prostate adenoma, and other disorders affecting the human reproductive system. |
Buy | - |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-09-20 |
M8 Pharmaceuticals
Brewyn, Pennsylvania, United States M8 Pharmaceuticals is a pharmaceutical company focused on licensing, marketing, and distributing therapeutics serving Brazil and Latin American markets. M8 Pharmaceuticals was founded in 2007 and is based in Berwyn, Pennsylvania. |
Buy | - |
| Category | Company |
|---|---|
| Founded | 1850 |
| Sector | Life Science |
| Employees | 8,612 |
| Revenue | 40.7B ZAR (2023) |
Aspen Pharmacare is a provider of specialty, branded, and generic pharmaceuticals, Aspen has an extensive basket of products that provide treatment for a broad spectrum of acute and chronic conditions experienced through all stages of life. The Group continues to increase the number of lives benefitting from its products, reaching more than 150 countries. In line with the Group’s commercial, production and territorial strategies, Aspen has identified thrombosis, anaesthetics, high potency & cytotoxics and infant nutritionals as four therapeutic categories which will get the highest focus based on materiality and future potential. Aspen Pharmacare was founded in 1850 and is based in Durban, South Africa.
| DEAL STATS | # |
|---|---|
| Overall | 2 of 2 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 2 of 2 |
| Country (South Africa) | 1 of 1 |
| Year (2022) | 1 of 1 |
| Size (of disclosed) | 1 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2020-09-08 |
Aspen Pharmacare Holdings - Thrombosis Business
United Kingdom Aspen Pharmacare's Thrombosis Business is a global offering comprised largely of a broad range of specialist injectable anticoagulants. Aspen's portfolio also includes Orgaran which is a heparin derivative (heparinoid) indicated for the treatment of HIT. HIT is an adverse reaction occurring in a limited number of patients undergoing heparin related therapy. It offers healthcare providers the advantage of a single supplier that addresses broad clinical needs and thus ensures the optimal care of patients at risk of thrombosis. |
Sell | €642M |
